NMD Pharma A/S: Financial statements 2025
CVR: 36899069
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475. The solvency ratio was 53.9%. The company had 49 employees in the financial year.
- Gross Profit
- EUR -26,063,175
- Profit/Loss
- EUR -32,985,370
- Equity
- EUR 12,410,475
- Total Assets
- EUR 23,005,016
- Employees
- 49
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -26.1 mio. EUR | -33 mio. EUR | 12.4 mio. EUR | 49 |
| 2024 | - | -27.9 mio. EUR | -32.3 mio. EUR | 35.4 mio. EUR | 36 |
| 2023 | - | -19.2 mio. EUR | -22.4 mio. EUR | 42.7 mio. EUR | 31 |
| 2022 | - | -9.5 mio. EUR | -12.3 mio. EUR | 25.1 mio. EUR | 26 |
| 2021 | - | -11 mio. EUR | -13.6 mio. EUR | 2.6 mio. EUR | 26 |
Official annual report
How creditworthy is NMD Pharma A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 12, 2025, is registered as an owner of NMD Pharma A/S with an ownership share of 10%.
As of August 12, 2025, is registered as an owner of NMD Pharma A/S with an ownership share of 33%.
NMD Pharma A/S has published its annual report for 2024. Gross profit came to DKK -27,874,344, and the net result was DKK -32,253,700.
As of May 1, 2025, Ivan Andreevich Burkov has joined the board of directors of NMD Pharma A/S.
As of May 1, 2025, Simone Botti has left the board of directors of NMD Pharma A/S.
As of February 13, 2025, João Carlos Ribas de Almeida has joined the board of directors of NMD Pharma A/S.
As of February 13, 2025, Morten Døssing has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.